Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00108537 · ClinicalTrials.gov registry record · Phase 3

Non-Nicotine Agents for Smoking Cessation

A Phase 3 study of Tobacco Use Disorder, sponsored by US Department of Veterans Affairs.

Completed
Registry status
Phase 3
Development phase
1
Study location

NCT00108537 is a Phase 3 study of Tobacco Use Disorder that has completed, run by US Department of Veterans Affairs. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00108537, a Phase 3 study of Tobacco Use Disorder, has completed, sponsored by US Department of Veterans Affairs.

COMPLETED
Registry status
Phase 3
Development phase
1
Study location

Study Summary

The primary objective of this study is to determine which is the better approach to smoking cessation in veterans: bupropion combined with transdermal nicotine or high dose nicotine replacement therapy (NRT) using transdermal nicotine combined with nicotine inhaler.

Conditions Studied

Interventions

  • DRUG bupropion and transdermal patch
  • DRUG transdermal patch and nicotine inhaler

Study Locations (1)

Colorado

  • Denver VA Medical Center - Denver

Trial Details

FieldValue
Start Date 2003-10
Est. Completion 2005-09
Phase Phase 3

Sponsor

US Department of Veterans Affairs

632 total trials

What the Registry Record Tells You About NCT00108537

The ClinicalTrials.gov registry entry for NCT00108537 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Tobacco Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which bupropion and transdermal patch is the first listed.

NCT00108537 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT00108537 about?

NCT00108537 is a clinical study titled "Non-Nicotine Agents for Smoking Cessation". The primary objective of this study is to determine which is the better approach to smoking cessation in veterans: bupropion combined with transdermal nicotine or high dose nicotine replacement therapy (NRT) using transdermal nicotine combined with nicotine inhaler.

What is the current status of trial NCT00108537?

This trial is currently completed. It is a Phase 3 study. The study started on 2003-10. Estimated completion is 2005-09.

What conditions does trial NCT00108537 study?

This clinical trial studies the following conditions: Tobacco Use Disorder.

What interventions are being tested in trial NCT00108537?

The interventions under investigation include: bupropion and transdermal patch (DRUG), transdermal patch and nicotine inhaler (DRUG).

Who is sponsoring clinical trial NCT00108537?

This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00108537 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.